Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.

Jain RK.

Science. 2005 Jan 7;307(5706):58-62. Review.

PMID:
15637262
2.
3.

Antiangiogenic therapy for cancer: current and emerging concepts.

Jain RK.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16. Review.

4.

Current strategies and future directions of antiangiogenic tumor therapy.

Zhang ZL, Wang JH, Liu XY.

Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai). 2003 Oct;35(10):873-80. Review.

5.

Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".

Rak J, Yu JL.

Semin Cancer Biol. 2004 Apr;14(2):93-104. Review.

PMID:
15018893
6.
7.

Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.

Sato Y.

Cancer Sci. 2011 Jul;102(7):1253-6. doi: 10.1111/j.1349-7006.2011.01929.x. Epub 2011 Apr 14. Review.

8.

Antiangiogenic therapy for the treatment of pediatric solid malignancies.

Davidoff AM, Kandel JJ.

Semin Pediatr Surg. 2004 Feb;13(1):53-60. Review.

PMID:
14765371
9.

Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment.

Teng LS, Jin KT, He KF, Wang HH, Cao J, Yu DC.

J Chin Med Assoc. 2010 Jun;73(6):281-8. doi: 10.1016/S1726-4901(10)70062-9. Review.

10.

Therapeutic targeting of the tumor vasculature.

Tozer GM, Bicknell R.

Semin Radiat Oncol. 2004 Jul;14(3):222-32. Review.

PMID:
15254865
11.

[A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].

Qiu H, Wang GM.

Ai Zheng. 2007 Dec;26(12):1392-6. Review. Chinese.

PMID:
18076810
12.
13.

Current development status of small-molecule vascular disrupting agents.

Chaplin DJ, Horsman MR, Siemann DW.

Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Review.

PMID:
16784022
14.

Tumor angiogenesis and therapy.

Cao Y.

Biomed Pharmacother. 2005 Oct;59 Suppl 2:S340-3. Review.

PMID:
16507405
15.
16.

Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.

De Bock K, Cauwenberghs S, Carmeliet P.

Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22. Review.

PMID:
21106363
17.

Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.

Tie J, Desai J.

Crit Rev Oncog. 2012;17(1):51-67. Review.

PMID:
22471664
18.

Vascular targeting therapy: potential benefit depends on tumor and host related effects.

Horsman MR, Bohn AB, Busk M.

Exp Oncol. 2010 Sep;32(3):143-8. Review.

PMID:
21403608
19.

Escape mechanisms after antiangiogenic treatment, or why are the tumors growing again?

Hlushchuk R, Makanya AN, Djonov V.

Int J Dev Biol. 2011;55(4-5):563-7. doi: 10.1387/ijdb.103231rh. Review.

20.

Supplemental Content

Support Center